<DOC>
	<DOCNO>NCT02968849</DOCNO>
	<brief_summary>This study evaluate preventive vaccine efficacy , safety , tolerability ALVAC-HIV ( vCP2438 ) + Bivalent Subtype C gp120/MF59 HIV-seronegative South African adult 24 month potentially 36 month enrollment .</brief_summary>
	<brief_title>Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety Efficacy Study South Africa</brief_title>
	<detailed_description>This study evaluate preventive vaccine efficacy , safety , tolerability ALVAC-HIV vaccine + Bivalent Subtype C gp120 protein adjuvanted MF59 HIV-seronegative South African adult 24 month enrollment . Participants randomize receive ALVAC-HIV ( vCP2438 ) , placebo , intramuscular injection week 0 4 ; receive ALVAC-HIV ( vCP2438 ) + Bivalent Subtype C gp120/MF59 , placebo , IM injection week 12 , 24 , 52 . In addition vaccination visit , participant attend study visit week 26 , 39 , 54 , 65 , 78 , 91 , 104 , 117 , 130 , 142 , 156 . All study visit , include vaccination visit , include HIV risk reduction counseling , physical exam , interview/questionnaire . pregnancy test participant capable become pregnant . Select study visit include medical history review , physical exam , blood collection , urine collection , HIV testing , pregnancy test participant capable become pregnant .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Inclusion Criteria Age 18 35 year Sexually active , define sexual intercourse least twice past 30 day prior screen , consider site staff risk HIV infection . Access participate HVTN CRS willingness follow plan duration study Ability willingness provide inform consent Assessment understanding : volunteer demonstrate understand study prior first vaccination verbal demonstration understanding question . Agrees enroll another study investigational research agent participant unblinded study participation end , whichever occur last Good general health show medical history , physical exam , screen laboratory test Willingness receive HIV test result Willingness discuss HIV infection risk willing receive HIV risk reduction counsel . Alanine aminotransferase ( ALT ) &lt; 2.5 time institutional upper limit normal Negative HIV1 2 blood test within 30 day prior enrollment : Sites may use locally available assay approve HVTN Laboratory Operations . Volunteers born female : negative serum urine beta human chorionic gonadotropin ( βHCG ) pregnancy test perform prior vaccination day initial vaccination . Persons NOT reproductive potential due undergone total hysterectomy bilateral oophorectomy ( verified medical record ) , require undergo pregnancy test . Reproductive status : A volunteer bear female must : Agree consistently use effective contraception ( Appendix B Appendix C ) sexual activity could lead pregnancy least 21 day prior enrollment 3 month last vaccination . Effective contraception define use 2 method birth control . These include 1 follow method : Condoms ( male female ) Diaphragm cervical cap PLUS 1 follow method : Intrauterine device ( IUD ) , Hormonal contraception ( accordance applicable national contraception guideline ) , Successful vasectomy male partner ( consider successful volunteer report male partner [ 1 ] documentation azoospermia microscopy , [ 2 ] vasectomy 2 year ago resultant pregnancy despite sexual activity postvasectomy ) , Any contraceptive method approve protocol safety review team ; Or reproductive potential , diagnosed premature menopause ( menses 1 year ) undergone hysterectomy , bilateral oophorectomy , tubal ligation . Volunteers born female must also agree seek pregnancy alternative method , artificial insemination vitro fertilization 3 month last vaccination Exclusion Criteria Blood product receive within 90 day first vaccination Investigational research agent receive within 30 day first vaccination Intent participate another study investigational research agent study require nonHVTN HIV antibody test plan duration study Pregnant breastfeeding HIV vaccine ( ) receive prior HIV vaccine trial . For volunteer receive control/placebo HIV vaccine trial , HVTN 702 PSRT determine eligibility casebycase basis . NonHIV experimental vaccine ( ) receive within last 5 year prior vaccine trial . Exceptions may make vaccine subsequently undergone licensure . For volunteer receive control/placebo experimental vaccine trial , protocol safety review team determine eligibility casebycase basis . For volunteer receive experimental vaccine ( ) great 5 year ago , eligibility enrollment determine protocol safety review team casebycase basis . Live attenuate vaccine influenza vaccine receive within 30 day first vaccination schedule within 14 day injection ( eg , measles , mumps , rubella [ MMR ] ; oral polio vaccine [ OPV ] ; varicella ; yellow fever ) Influenza vaccine vaccine live attenuate vaccine receive within 14 day prior first vaccination ( eg , tetanus , pneumococcal , Hepatitis A B ) Immunosuppressive medication receive within 168 day first vaccination . ( Not exclusionary : [ 1 ] corticosteroid nasal spray ; [ 2 ] inhaled corticosteroid ; [ 3 ] topical corticosteroid mild , uncomplicated dermatitis ; [ 4 ] single course oral/parenteral corticosteroid dose &lt; 2 mg/kg/day length therapy &lt; 11 day completion least 30 day prior enrollment . ) Serious adverse reaction vaccine vaccine component egg , egg product , neomycin include history anaphylaxis relate symptom hive , respiratory difficulty , angioedema , and/or abdominal pain . ( Not exclude participation : volunteer nonanaphylactic adverse reaction pertussis vaccine child . ) Immunoglobulin receive within 60 day first vaccination Immunodeficiency Clinically significant medical condition , physical examination finding , clinically significant abnormal laboratory result , past medical history clinically significant implication current health . A clinically significant condition process include limit : A process would affect immune response , A process would require medication affect immune response , Any contraindication repeat injection blood draw , A condition require active medical intervention monitoring avert grave danger volunteer 's health wellbeing study period , A condition process sign symptom could confuse reaction vaccine , Any condition specifically list among exclusion criterion . Any medical , psychiatric , occupational , condition , judgment investigator , would interfere , serve contraindication , protocol adherence , assessment safety reactogenicity , volunteer 's ability give inform consent Psychiatric condition precludes compliance protocol . Specifically excluded person psychosis within past 3 year , ongoing risk suicide , history suicide attempt gesture within past 3 year . Active tuberculosis ( TB ) disease Uncontrolled hypertension : systolic blood pressure ( SBP ) ≥ 160 mm Hg diastolic blood pressure ( DBP ) ≥ 100 mm Hg Bleeding disorder ( diagnosed doctor ) contraindicate IM injection and/or blood draw , base investigator 's judgment Malignancy ( Not exclude participation : Volunteer malignancy excise surgically , investigator 's estimation , reasonable assurance sustain cure unlikely experience recurrence malignancy period study ) History hereditary angioedema , acquire angioedema , idiopathic angioedema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HIV</keyword>
</DOC>